Biotech’s Declaration Of Independence And What Pharma Needs To Do About It

By Ben Bonifant (Contributor), Jeff Stewart (Contributor) / Email the Authors / IN VIVO January 2012, Vol. 30, No. 1
Around The Industry / Word Count: 2186 / Article # 2012800007

Executive Summary

After a long period when only the bravest, well-funded biotechs attempted to build a commercial organization, more companies than ever are taking the go-it-alone plunge. Campbell Alliance thinks we may look back on the commercializing classes of 2011–2012 for key lessons on what drives success, which companies created value and how, and when market challenges prove too much for a new organization.